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Abstract
Most of the time, polycystic ovary syndrome (PCOs) is considered as an obese women
disease; lean PCOs patients need to evaluate and treat completely as a neglected subgroup.
Androgen excess signs and symptoms, insulin resistance (IR) and its consequences, cardio-
metabolic risks, and regular exercise must be noted and managed carefully.
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1. Introduction
Polycystic ovary syndrome (PCOs) is the most common reason of androgen excess in
reproductive-age women with a prevalence of 6.5–8% according to clinical appearance [1] or
even up to 20% by sonographic evidence [2].
For the first time, Stein and Leventhal described it in the year 1935 [3]. Year after year, the
description of the disease developed; in 1990, the National Institutes of Health (NIH) men-
tioned oligo-ovulation and hyperandrogenism with or without hyperandrogenemia (HA)
must be together (of course, after exclusion of another causes of androgen excess) [4].
Another expert meeting in 2003 expanded the NIH definition of PCOs by adding the sono-
graphic aspect of the disease (Rotterdam criteria) [5]. According to their criteria, two of three
signs/symptoms are necessary for PCOs diagnosis; therefore, PCOs woman can be ovulatory
with regular menstruation.
More recently, the Androgen Excess Society (AES) advocated that all of the signs and symp-
toms should be present for the confirmation of diagnose [6] (Table 1).
Contrary to physicians’ and patients’ belief, weight or body mass index (BMI) had never been
a part of PCOs definition.
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According to epidemiological data, there is a wide variation in the prevalence of obese and
non-obese PCOs women: in Korean population 20%, in Europe 27–50.5%, and in USA 67% of
PCOs woman are obese [7–11]. Regarding to different ethnicity, the prevalence of normal
weight and underweight patients with PCOs has been reported 1.5–6.6% [12, 13]. Entirely, by
using Rotterdam criteria, the overall prevalence of PCOs is increasing because ovulatory or
non-hyper androgen PCO patients also are considered [14].
By definition, women with BMI ≤ 25 are non-obese and with BMI > 25 considered obese.
Although at now, we have a few reports about the prevalence of non-obese PCOs patients, but
attention toward those patients and theirmetabolic andhealth problems are enhancedday byday.
The pathophysiology of PCOs is multifactorial and manifests the final effect of genetic, fetal,
environmental, and metabolic factors. As a result of weakness or strength of each factor,
clinical and subclinical character and their response to therapeutic efforts will be different.
2. Genetic and PCOs
Obvious familial clustering of PCOs and higher prevalence of its sign and symptom, like type 2
diabetes mellitus (T2DM) and hyperandrogenemia in first-degree relatives of women with PCOs,
demonstrate its genetic origin [15, 16]. Also, in the Dutch twin study, higher degree of heritability
was shown [17]. Initially, autosomal dominant mode of inheritance was suggested [18]; but after a
while, researches demonstrate it has more complex inheritance pattern. Despite the progress in
genes or loci study, no single gene has been successfully described as the certain responsible gene
among all studies [19]. According to microarray analysis results, 14 important genes were recog-
nized: 6 genes were identified as down-regulated genes and 8 genes as up-regulated genes [20].
Another proposed genes are CYP11A, the insulin gene, and a region near the insulin-receptor
gene [21]. Also, controlling genes in folliculogenesis and LH receptor and coding genes for TNF-
alpha, IL-6, and IL-6 receptor can be involved in the pathogenesis of this syndrome [22].
NIH Criteria 1990 (all of them) ESHRE
1
/ASRM
2
(Rotterdam) 2003 (two of three) AES 2006 (all of them)
Hyperandrogenism  hyperandrogenemia Hyperandrogenismhyperandrogenemia Hyperandrogenism 
hyperandrogenemia
Oligo-ovulation Menstruation abnormality Ovarian dysfunction 
sonographic aspect
Sonographic aspect of poly cystic ovary
Exclusion of other androgen excess conditions is necessary for all of definition: (21-hydroxylase deficient, thyroid dys-
function, nonclassical adrenal hyperplasia, hyper prolactinemia, drug-induced androgen excess, androgenic neoplasm,
Cushing syndrome, growth hormone excess).
1European Society for Human Reproductive Medicine.
2American Society for Reproductive Medicine.
Table 1. Different definition of polycystic ovary syndrome.
Debatable Topics in PCOS Patients24
3. Insulin and PCOs
For the first time in 1980, the relation between this syndrome and insulin was determinate [23].
Clinically insulin resistance (IR) is specified as inability of a known amount of endogenous or
exogenous insulin to enhance glucose uptake and consumption. As a result of a misbelief that
IR always accompanies with obesity, in clinical practice, IR is underestimated in non-obese
PCO women. IR is a common character between obese and non-obese PCO patients and its
overall prevalence is 50–75%. Up to 35% of PCOs women have IGTT and 7–10% are type 2
diabetes mellitus (T2DM) [24].
At now, the most used IR indices are homeostasis-model assessment (HOMA) and insulinemic
2-h area under the curve (AUCi 2 h), both derived from oral glucose tolerance test (OGTT) [25].
The 120-min glucose and insulin evaluation (HOMA-M120) is the best IR index in lean PCOs
women according to Morciano et al. study [26]. Meanwhile, there are several earlier studies
about IR evaluation in lean PCOs women [27–29]. Although, a study in a large group of
European lean PCOs patients displayed that this group had significantly less IR compared
with obese PCO women [30]; but, instead of it, there is evidence that in American and Asian
PCOs women, IR is independent from BMI [31]. It seems that dietary composition and ethnic
background associated with this discrepancy.
Owing to another recent study, the crucial role of insulin in PCO pathogenesis empha-
sized that IR shall be evaluated even in normal weight and lean PCOs patients [12].
As suggested in the earlier study [32], hyperinsulinemia stimulates ovarian P450c17 alpha
activity in non-obese women with PCOs, which means more conversion of progesterone to
androstenedione which is changed to testosterone. In granulosa cell, insulin intensifies their
response to LH. Therefore, these cells experience premature arrest of follicular growth and
abnormal differentiation, and thus anovulation. Also, elevated insulin resistance causes hyper-
glycemia which leads to hyperinsulinemia and it can increase LH action on theca cells and
subsequent elevation in androgen level. Hyperinsulinemia, insulin resistance, and enhance-
ment in androgen production are the famous pathophysiology triads in PCOs. From another
side, elevated level of insulin prevents hepatic sex hormone-binding globulin (SHBG) produc-
tion, which can lead to elevated free androgen and again elevated level of insulin, a positive
feedback in an undesirable circle. Thus, IR and hyperinsulinemia are the principal pathological
causes of this syndrome, and hyperandrogenemia is their consequence.
As insulin resistance has fundamental role in non-obese PCOs patients, then metformin
administration have a beneficial effect on them and regulate their menstruation cycle [33]. As
well, there is a new therapeutic option: inositol, a precursor component of second messenger
for follicle-stimulating hormone (FSH), thyroid - stimulating hormone (TSH), and insulin recep-
tor. This drug can overcome IR from another way [34]. It is important to mention that only 15%
of women with IR are having PCOs criteria; therefore, insulin resistance cannot be the only
pathophysiologic pathway [35] and metformin administration may not be effective in all of
lean PCOs.
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4. Androgens and PCO
About 10–12% of women in reproductive age suffer from androgen excess sign and symptom.
It can be caused by androgen overproduction (from ovary or adrenal gland) or secondary to
increased sensitivity of pilosebaceous unit (with normal level of androgens). Hyperandrogenemia
is another hallmark of PCOs; mainly by ovarian resource and less by adrenal. In PCOs women,
60% of serum androstenedione and testosterone (T) are secreted by ovary. Surprising, ovarian
androgens will not prominently affect LH production, thus an elevation in free testosterone
or androstenedione will not decrease ovarian synthesis of these androgens in women, contrasting
to men.
As mentioned before, in PCO women, insulin in a solitary manner or with synergetic effect of
LH induces androgen production by ovaries. Even in lean PCOs women with normal meta-
bolic insulin sensitivity and insulin levels, decline of insulin secretion with diazoxide (like
metformin) prominently reduce levels of free Tand androstenedione andmeaningfully increased
SHBG [36]. In these women, hyperandrogenemia is seen because of augmented sensitivity of
their androgenic pathway to insulin and dysregulation of steroidogeneses enzymes based on
genetic predisposition [37]. Therefore, even in PCOs patients with normal insulin metabolic and
without clinical approved IR, local resistance in the ovaries increased androgens production [38].
Androgen excess or hyperandrogenemia (HA) in PCOs women contribute in exacerbation of
metabolic abnormalities, such as insulin resistance in adipose tissue and skeletal muscle and
elevation in lipid metabolism in visceral fat, decreased lipolysis in subcutaneous fat, increased
low-density lipoprotein cholesterol (LDL-C) levels decreased HDL-C levels. Besides that,
androgens may be involved in possible direct vascular action [39]. There are some studies, in
which hyperandrogenemia was accompanying with metabolic syndrome (MetS) in non-obese
PCOs more than obese PCOs women [40, 41].
Hyperandrogenemia or androgen access clinical signs are mainly cutaneous manifestations:
hirsutism, acne, androgenic alopecia, acanthosis nigricans (AN), and seborrhea. In one study,
their prevalence in PCOs women was: 78, 48, 31, 30, and 29% (in mentioned order) [42]. In
another study, the prevalence of acanthosis nigricans in obese PCO was 42.5% compared to
28% in non-obese [43]. One published paper shows that AN is a marker of hyperinsulinemia in
both obese and non-obese PCO patients rather than a sign of androgen excess and the only sex
steroid associated with histological AN is dehydroepiandrosterone sulfate (DHEAS) [44].
Pharmacological management of hyperandrogenic skin symptoms has two targets: firstly,
decrease the level of circulating androgens, and secondly prevent their effect at tissue level.
Cyproterone acetate/ethinylestradiol has beneficial effect in non-obese PCO women with
hyperandrogenic skin symptoms [45].
5. Inflammation and PCO
There are many published studies about proinflammatory or inflammatory situations in PCOs
woman. Increased level of circulatory inflammatory markers like C-reactive protein (CRP),
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tumor necrosis factor-alpha (TNF-α), interleukins (IL-16 and -18), and plasminogen activator
inhibitor in PCO patients accompany with abdominal obesity and more specific with visceral
fat [46]. Low-grade inflammation situation by increased level of adiponectin, resistin, IL-6,
and TNF-α in non-obese PCO women have been approved [47]. Also, it has been shown that
inhibition of nutrient-induced inflammation decreases ovarian androgen secretion and
induces ovulation in lean PCOs woman without clinical IR or abdominal adiposity. There-
fore, inflammation directly encourages ovarian dysfunction in PCOs women distinctly
from insulin resistance or excess adiposity [48]. There is evidence that non-steroidal
anti-inflammatory agent administration in lean PCO women can reduce androgen secretion
from ovary [49].
Dose inflammation have pathophysiologic role in this syndrome or may be its consequence
remain still unclear. Inflammation as a chronic immune activation, prevents ovulation,
increases androgen production by ovary and adrenal gland and disrupts hormonal receptors.
Most of long-term complications of PCOs like cardiovascular disease (CVD) are consequences
of inflammatory state [50].
In non-obese PCO patients, visceral fat distribution, waist to hip ratio (WHR), and abdominal
obesity have relation with inflammatory situation. In one study, in lean PCOs, level of white
blood cell (WBC) has a positive predictive value with insulin resistance, while the neutrophil to
lymphocyte ratio has a negative predictive value [51]. Also, it has been demonstrated that in
clomiphene citrate (CC)-resistant patients, regardless to BMI, inflammatory markers like TNF-
α are too high, and TNF-α serum level may be used as a clinical predictive indicator before CC
useless administration [52].
6. Weight and PCO
Even in lean PCO women, we can see higher waist to hip ratio, greater intra peritoneal
and visceral fat, and percentage of body fat in comparison with BMI matched non-PCO
women. Accumulation of small subcutaneous abdominal fat in those patients shows spoiled
adipogenesis and hyperandrogenism [53]. Also, abnormal gene expression in stem cell of sub-
cutaneous abdominal fat in normoandrogen and ovulatory lean PCO women display abnormal
vacuolization and angiogenesis, which may reflect metabolism alter in those women [54]. From
another side, adiponectin, a protein which is involved in regulating glucose levels and fatty acid
breakdown, is produced by omental fat and dysregulated by high level of insulin; thus, even
in lean PCOs women, inappropriate metabolism of glucose and lipid can be explained [55].
In respect with a new randomized controlled trial, arranged and regular physical exercise
can ameliorate insulin sensitivity, hyperandrogenemia, and menstrual regularity in lean PCO
women [56].
7. Metabolic disorders and PCO
PCOs is considered by multiple metabolic disorders which may associate to increase risk of
hypertension and cardiovascular disease. One study used menstrual irregularity as a predictive
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factor for assessment of cardiovascular events in a 15-year period, in PCOswomen. There was an
insignificant increase in overall stroke risk and in ischemic stroke risk associated with “very
irregular”menstrual cycles [57]. In PCO women, higher prevalence of hypertension is related to
insulin. Hyperinsulinemia have been connected with an increase in intracellular sodium and
calcium, along with vascular smooth muscle hypertrophy due to insulin-like growth factor-1
(IGF-1) activity [58]. Simultaneously, androgen excess stimulates sympathetic nerve activity, as
another etiology of hypertension in this population [59].
PCOs is also associated with elevated levels of plasma endothelin-1 (ET-1), one of several
circulating indicators of endothelial injury and dysfunction. One study found that impairment
of endothelial function is more severe in lean than obese women with PCOs, and that ET
receptor downregulation plays an essential role in this probably adverse cardiovascular out-
come [60].
The increase in carotid intima-media wall thickness (CIMT) in PCOs women has been associ-
ated in different studies with higher levels of insulin, hyperandrogenism, LDL level, and
abdominal obesity; which is an early marker of atherosclerosis [61].
Meanwhile, impaired nitric oxide (NO) production as a consequence of elevated androgen
levels in PCOs women contribute to endothelial dysfunction [62].
Elevated plasma viscosity as a result of increased plasma fibrinogen concentration in PCOs
patients exacerbates vascular dysfunction because autoregulation of vasomotor tone may not
be able to adjust with compromised physical properties of blood [63]. Some possible reasons
for increased plasma fibrinogen are: increased inflammatory processes [64], decreased fibrino-
lysis [65], and as an acute phase reactant. Enhancement in fibrinogen level stimulates RBC
aggregation and significantly increased resistance in blood flow [66]. Low SHBG and high
insulin stimulate prothrombotic state in all of PCOs women by increased plasminogen activa-
tor inhibitor 1 (PAI-1) activity and fibrinogen in a BMI-independent way [67].
Dyslipidemia including elevated low-density lipoprotein (LDL), triglyceride levels and decreased
high-density lipoprotein (HDL) are often seen in PCO women as a result of hyperandrogenism
and insulin resistance in both lean and obese PCO patients [68].
Owing to many evidence about vitamin D deficiency and metabolic syndrome; there are many
studies about 25(OH) D levels and PCOs. There are some evidences which support this
relationship and encourage vitamin D administration in all of deficient PCOs women [69],
whereas some studies do not support it [70].
From another site, insulin resistance, increased central adiposity, higher levels of testosterone,
and dyslipidemia beside oxidative stress and low grade inflammation contribute to cause
hepatic steatosis or fatty liver in PCOs women. Advanced stage of this disease characterized
by necrosis and steatohepatitis which called non-alcoholic fatty liver disease (NAFLD) and has
prevalence about 40% in lean PCOs women [71].
After blow-by-blow discussion about all of aspects in lean PCOs women, we cannot consider
this syndrome as just a part of infertility or menstrual abnormality assessment, but should be
accepted as an alarm sign for serious health problem.
Debatable Topics in PCOS Patients28
Author details
Elham Pourmatroud
Address all correspondence to: e.pourmatroud@yahoo.com
Sarem Women Hospital, Tehran, Iran
References
[1] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and
features of the polycystic ovary syndrome in an unselected population. The Journal of
Clinical Endocrinology and Metabolism. 2004;89(6):2745-2749. DOI: 10.1210/jc.2003-032046
[2] Botsis D, Kassanos D, Pyrgiotis E, Zourlas PA. Sonographic incidence of polycystic
ovaries in a gynecological population. Ultrasound in Obstetrics & Gynecology. 1995;6(3):
182-185. DOI: 10.1046/j.1469-0705.1995.06030182.x
[3] Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Ameri-
can Journal of Obstetrics and Gynecology. 1935;29(2):181-191. DOI: http://dx.doi.org/
10.1016/S0002-9378(15)30642-6
[4] Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Reviews
in Obstetrics & Gynecology. 2011;4(2):45-51 PMCID: PMC3218544
[5] The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised
2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary
syndrome (PCOS). Human Reproduction. 2004;19(1):41-47 PMID: 14688154
[6] Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF,
Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic
ovary syndrome: the complete task force report. Fertility and Sterility. 2009;91(2):456-488.
DOI: 10.1016/j.fertnstert.2008.06.035
[7] Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between
American and Italian women with polycystic ovary syndrome: Influence of the diet.
Human Reproduction. 2003;18(11):2289-2293 PMID: 14585875
[8] Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG,
et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal
and metabolic profile. The Journal of Clinical Endocrinology and Metabolism. 1999;84(11):
4006-4011. DOI: doi.org/10.1210/jcem.84.11.6148
[9] Knochenhauer ES, Key TJ, Kahsar-Miller M,WaggonerW, Boots LR, Azziz R. Prevalence of
the polycystic ovary syndrome in unselected black and white women of the southeastern
United States: A prospective study. The Journal of Clinical Endocrinology and Metabolism.
1998;83(9):3078-3082. DOI: 10.1210/jcem.83.9.5090
Lean Women with Polycystic Ovary Syndrome
http://dx.doi.org/10.5772/intechopen.70621
29
[10] Kim JJ, Hwang KR, Choi YM, Moon SY, Chae SJ, Park CW, et al. Complete phenotypic
and metabolic profiles of a large consecutive cohort of untreated Korean women with
polycystic ovary syndrome. Fertility and Sterility. 2014;101(5):1424-1430. DOI: 10.1016/j.
fertnstert.2014.01.049
[11] Kyrkou G, Trakakis E, Attilakos A, Panagopoulos P, Chrelias C, Papadimitriou A, et al.
Metabolic syndrome in Greek women with polycystic ovary syndrome: Prevalence, char-
acteristics and associations with body mass index. A prospective controlled study. Archives
of Gynecology and Obstetrics. 2016;293(4):915-923. DOI: 10.1007/s00404-015-3964-y
[12] Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen profile in
underweight women with polycystic ovary syndrome. Archives of Gynecology and
Obstetrics. 2017;296(2):363-371. DOI: 10.1007/s00404-017-4422-9
[13] Sheng Y, Lu G, Liu J, Liang X, Ma Y, Zhang X, et al. Effect of body mass index on the
outcomes of controlled ovarian hyperstimulation in Chinese women with polycystic
ovary syndrome: A multicenter, prospective, observational study. Journal of Assisted
Reproduction and Genetics. 2017;34(1):61-70. DOI: 10.1007/s10815-016-0830-1
[14] March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of
polycystic ovary syndrome in a community sample assessed under contrasting diagnos-
tic criteria. Human Reproduction. 2010;25(2):544-551. DOI: 10.1093/humrep/dep399
[15] Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history
of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. The
Journal of Clinical Endocrinology and Metabolism. 2005;90:66-71. DOI: 10.1210/jc.2004-
0229
[16] Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for
hyperandrogenemia in polycystic ovary syndrome. Proceedings of the National Acad-
emy of Sciences of the United States of America. 1998;95:14956-14960 PMCID: PMC24557
[17] Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syn-
drome in a Dutch twin-family study. The Journal of Clinical Endocrinology and Metabo-
lism. 2006;91:2100-2104. DOI: 10.1210/jc.2005-1494
[18] Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal
dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families. The
Journal of Clinical Endocrinology and Metabolism. 1999;84(1):38-43. DOI: 10.1210/
jcem.84.1.5382
[19] Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Molecular and Cellu-
lar Endocrinology. 2013;373:29-38. DOI: 10.1016/j.mce.2012.10.009
[20] Panda PK, Rane R, Ravichandran R, Singh S, Panchal H. Genetics of PCOS: A systematic
bioinformatics approach to unveil the proteins responsible for PCOS. Genomics Data.
2016;8:52-60. DOI: 10.1016/j.gdata.2016.03.008
Debatable Topics in PCOS Patients30
[21] Legro RS, Strauss JF. Molecular progress in infertility: Polycystic ovary syndrome. Fertil-
ity and Sterility. 2002;78:569-576 PMID: 12215335
[22] De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic,
hormonal and metabolic aspects of PCOS: An update. Reproductive Biology and Endo-
crinology. 2016;14(1):38-50. DOI: 10.1186/s12958-016-0173-x
[23] Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsu-
linism in polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabo-
lism. 1980;50:113-116. DOI: 10.1210/jcem-50-1-113
[24] O'MearaNM,Blackman JD,EhrmannDA,BarnesRB, Jaspan JB,RosenfieldRL, PolonskyKS.
Defects in beta-cell function in functional ovarian hyperandrogenism. The Journal of Clinical
Endocrinology andMetabolism. 1993;76(5):1241-1247. DOI: 10.1210/jcem.76.5.8496316
[25] Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeo-
stasis model assessment closely mirrors the glucose clamp technique in the assessment of
insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and
insulin sensitivity. Diabetes Care. 2000;23:57-63 PMID: 10857969
[26] Morciano A, Romani F, Sagnella F, Scarinci E, Palla C, Moro F, et al. Assessment of insulin
resistance in leanwomenwith polycystic ovary syndrome. Fertility and Sterility. 2014;102(1):
250-256. DOI: 10.1016/j.fertnstert.2014.04.004
[27] Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinc-
tive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes.
1992;41:1257-1266 PMID: 1397698
[28] Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients
with polycystic ovarian disease. The Journal of Clinical Endocrinology and Metabolism.
1983;57:356-359. DOI: 10.1210/jcem-57-2-356
[29] Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance,
independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174 PMID:
2670645
[30] Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, et al. Insulin sensitiv-
ity in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and
Metabolism. 2004;89:2942-2945. DOI: 10.1210/jc.2003-031378
[31] Takeuchi T, Tsutsumi O, Taketani Y. Abnormal response of insulin to glucose loading and
assessment of insulin resistance in nonobese patients with polycystic ovary syndrome.
Gynecological Endocrinology. 2008;24:385-391. DOI: 10.1080/09513590802173584
[32] Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to
insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
The Journal of Clinical Endocrinology and Metabolism. 1997;82(12):4075-4079. DOI:
10.1210/jcem.82.12.4431
Lean Women with Polycystic Ovary Syndrome
http://dx.doi.org/10.5772/intechopen.70621
31
[33] Al-Ozairi E, Quinton R, Advani A. Therapeutic response to metformin in an underweight
patient with polycystic ovarian syndrome. Fertility and Sterility. 2008;90(4):1197.e1-1197.e4.
DOI: 10.1016/j.fertnstert.2007.11.041
[34] Genazzani AD. Inositol as putative integrative treatment for PCOS. Reproductive Bio-
medicine Online. 2016;33(6):770-780. DOI: 10.1016/j.rbmo.2016.08.024
[35] Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of
ovarian hyperandrogenism. Fertility and Sterility. 1988;50(2):197-212 PMID: 3294042
[36] Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women
with polycystic ovary syndrome and normal insulin sensitivity. Fertility and Sterility.
2007;88(4):10-16. DOI: 10.1016/j.fertnstert.2006.12.055
[37] Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, ste-
roidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic
acids are overexpressed in thecal and granulosa cells from polycystic ovaries. The Journal
of Clinical Endocrinology and Metabolism. 2001;86(3):1318-1323. DOI: 10.1210/jcem.86.
3.7318
[38] Wu XK, Zhou SY, Liu JX, Pollanen P, Sallinen K, Makinen M, et al. Selective ovary
resistance to insulin signaling in women with polycystic ovary syndrome. Fertility and
Sterility. 2003;80:954-965 PMID: 14556818
[39] Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberra-
tions and cardiovascular risk in women with polycystic ovary syndrome. Women's
Health. 2009;4:583-594. DOI: 10.2217/17455057.4.6.583
[40] Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome
and insulin resistance according to the phenotypic subgroups of polycystic ovary syn-
drome in a representative sample of Iranian females. Journal of Research in Medical
Sciences. 2011;16:763-769 PMCID: PMC3214394
[41] Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ, et al. Prevalence of metabolic
syndrome is higher among non-obese PCOS women with hyperandrogenism and men-
strual irregularity in Korea. PloS One. 2014;9(6):e99252. DOI: 10.1371/journal.pone.0099252
[42] Abid Keen M, Hassan Shah I, Sheikh G. Cutaneous manifestations of polycystic ovary
syndrome: A cross-sectional clinical study. Indian Dermatology Online Journal. 2017;8(2):
104-110. DOI: 10.4103/2229-5178.202275
[43] IbrahimMahmoud M, Habeebc F, Kasim K. Reproductive and biochemical changes in
obese and non-obese polycystic ovary syndrome women. Alexandria Journal of Medi-
cine. 2015;51(1):5-9. DOI: doi.org/10.1016/j.ajme.2014.03.002
[44] Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis Nigricans,
insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings.
The Journal of Clinical Endocrinology and Metabolism. 1991;73(3):590-595. DOI: 10.1210/
jcem-73-3-590
Debatable Topics in PCOS Patients32
[45] Bitzer J, Römer T, Lopes da Silva Filho A. The use of Cyproterone acetate/ethinyl estradiol
in hyperandrogenic skin symptoms—A review. The European Journal of Contraception
& Reproductive Health Care. 2017;22(3):172-182. DOI: dx.doi.org/10.1080/13625187.20
17.1317339
[46] Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1
release is higher in visceral than subcutaneous human adipose tissue (AT): Implication
of macrophages resident in the AT. The Journal of Clinical Endocrinology and Metabo-
lism. 2005;90(4):2282-2289. DOI: 10.1210/jc.2004-1696
[47] Y-X WANG, W-J ZHU. Evaluation of adiponectin, resistin, IL-6, TNF-α in obese and non-
obese women with polycystic ovary syndrome. Journal of Reproduction and Contracep-
tion. 2012;23(4):237-244. DOI: doi.org/10.1016/S1001-7844(12)60032-7
[48] Gonzalez F, Mather KJ, Considine RV, Pardue SL, Acton AJ. Suppression of nutrient-
induced inflammation with a nonsteroidal anti-inflammatory agent ameliorates ovarian
dysfunction in lean insulin-sensitive women with polycystic ovary syndrome (PCOS).
Fertility and Sterility. 2015;14(3):e21. DOI: 10.1016/j.fertnstert.2015.07.064
[49] Gonzalez F, Considine RV, Abdelhadi OA, Acton AJ. Anti-inflammatory therapy suppresses
proinflammatory cytokine secretion frommononuclear cells and reduces hyperandrogenism
in lean women with polycystic ovary syndrome (PCOS). Fertility and Sterility. 2016;106(3):
e32. DOI: 10.1016/j.fertnstert.2016.07.104
[50] Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic
ovarian syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biol-
ogy. 2015;191:15-22. DOI: 10.1016/j.ejogrb.2015.05.005
[51] Tola EN, Yalcin SE, Dugan N. The predictive effect of inflammatory markers and lipid
accumulation product index on clinical symptoms associated with polycystic ovary syn-
drome in non-obese adolescents and younger aged women. European Journal of Obstet-
rics, Gynecology, and Reproductive Biology. 2017;214:168-172. DOI: 10.1016/j.ejogrb.20
17.05.014
[52] Seyam E, Hasan M, Khalifa EM, Ramadn A, Hefzy E. Evaluation of tumor necrosis factor
alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic
ovary disease. Gynecological Endocrinology. 2017;8:1-7. DOI: 10.1080/09513590.2017.
1320383
[53] Akopians AL, Madrigal V, Fisch S, Ramirez E, Margolis D, Sarma MK, et al. Hyperandro
genism is associated with preferential fat deposition of visceral versus subcutaneous (SC)
abdominal fat in lean polycystic ovary syndrome (PCOS) women. Fertility and Sterility.
2016;106(3):Supp:e31-Supp:e32. DOI: 10.1016/j.fertnstert.2016.07.102
[54] Phan J, Madrigal VK, Guedikian A, Li X, Dumesic DA, Chazenbalk GD. Immunological,
structural and stem cell characteristics of subcutaneous (SC) abdominal adipose in lean
polycystic ovary syndrome (PCOS) women versus normoandrogenic ovulatory (NL)
women. Fertility and Sterility. 2016;106(3):supp:e250. DOI: 10.1016/j.fertnstert.2016.07.722
Lean Women with Polycystic Ovary Syndrome
http://dx.doi.org/10.5772/intechopen.70621
33
[55] Seow KM, Tsai YL, Juan CC, Lin YH, Hwang JL, Ho LT. Omental fat expression of
adiponectin and adiponectin receptors in non-obese women with PCOS: A preliminary
study. Reproductive Biomedicine Online. 2009;19(4):577-582 PMID:19909601
[56] Bisgaard H, Dela F. Physical exercise is a help for lean women with polycystic ovary
syndrome. Ugeskrift for Laeger. 2017;179(23): PMID: 28606299
[57] Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, et al. Men-
strual cycle irregularity and risk for future cardiovascular disease. The J Clin Endocrinol
Metab. 2002 May;87(5):2013-17. DOI: 10.1210/jcem.87.5.8471
[58] Zavaroni I, Coruzzi P, Bonini L, Mossini GL, Musiari L, Gasparini P, et al. Association
between salt sensitivity and insulin concentrations in patients with hypertension. Amer-
ican Journal of Hypertension. 1995;8(8):855-858. DOI: 10.1016/0895-7061(95)00152-F
[59] Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic
ovary syndrome associated with high sympathetic nerve activity and size at birth?
American Journal of Physiology. Endocrinology and Metabolism. 2008;294:E576-E581.
DOI: 10.1152/ajpendo.00725.2007
[60] Usselman CW, Taylor HS, Stachenfeld NS. Microvascular endothelial function in lean
versus obese women with polycystic ovary syndrome: Role of the endothelin B receptor.
Gynecological Endocrinology. 2007;23(10):604-609. DOI: 10.1096/fj.1530-6860
[61] Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: Important underrecognised
cardiometabolic risk factor in reproductive-age women. International Journal of Endocrinol-
ogy. 2015;786362. DOI: 10.1155/2015/786362
[62] Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated
with endothelial dysfunction. Circulation. 2001;103(10):1410-1415 PMID: 11245645
[63] Vervita V, Saltamavros AD, Adonakis G, Tsapanos V, Decavalas G, Georgopoulos NA.
Obesity and insulin resistance increase plasma viscosity in young women with polycystic
ovary syndrome. Gynecological Endocrinology: The Official Journal of the International
Society of Gynecological Endocrinology. 2009;25(10):640-646. DOI: 10.1371/journal.pone.
0167290
[64] Gonzalez F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance
and ovarian dysfunction. Steroids. 2012;77(4):300-305. DOI: 10.1016/j.steroids.2011.12.003
[65] Burchall GF, Piva TJ, Linden MD, Gibson-Helm ME, Ranasinha S, Teede HJ. Comprehen-
sive assessment of the hemostatic system in polycystic ovarian syndrome. Seminars in
Thrombosis and Hemostasis. 2015. DOI: 10.1055/s-0035-1564837
[66] Simmonds MJ, Milne N, Ong K, Brotherton E, McNamee AP, Horobin J, Sabapathy S.
Physical properties of blood are altered in young and lean women with polycystic ovary
syndrome. PLoS One. 2016;11(11):e0167290. DOI: 10.1371/journal.pone.0167290
[67] Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E.
Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Debatable Topics in PCOS Patients34
The Journal of Clinical Endocrinology and Metabolism. 2011;96(4):1068-1076. DOI:
10.1210/jc.2010-2279
[68] Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic
disorders in nonobese patients with polycystic ovary syndrome. Fertility and Sterility.
2003;79(6):1358-1364 PMID:12798883
[69] Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B.
Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syn-
drome. European Journal of Endocrinology. 2009;161(4):575-582. DOI: 10.1530/EJE-09-0432
[70] Rashidi H, Najafian M, Toolabi M, Safapoor N, Sadrian E, Nazari P. The relationship of
serum 25-dihydroxy vitamin D3 concentrations with metabolic parameters in non-obese
women with polycystic ovarian syndrome. Middle East Fertility Society Journal. 2016;
21(4):264-268. DOI: 10.1016/j.mefs.2016.06.003
[71] Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W.
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Clinical Gastroenterology and Hepatology. 2007;5(4):496-501. DOI: 10.1016/j.cgh.2006.10.010
Lean Women with Polycystic Ovary Syndrome
http://dx.doi.org/10.5772/intechopen.70621
35

